X-Linked Hypophosphatemia (XLH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

X-linked hypophosphatemia (XLH) is a hereditary disorder affecting phosphate metabolism. It arises from mutations in the Phosphate Regulating Endopeptidase Homolog, X-Linked (PHEX) gene. These mutations result in local and systemic effects, encompassing impaired growth, bone pain, osteomalacia, bone deformities, rickets, spontaneous dental abscesses, osteoarthritis, enthesopathy, hearing issues, and muscular dysfunction. XLH patients exhibit elevated levels of fibroblast growth factor 23 (FGF23). Diagnosis relies on a consistent medical history, physical examination, radiological evidence of rickets, biochemical tests, and a family history indicating the presence of XLH, whether through multiple generations or sporadic occurrences. The differential diagnosis should consider nutritional rickets, metaphyseal dysplasia, and other renal phosphate wasting disorders. Fibroblast growth factor 23 (FGF23) is primarily produced by osteocytes and osteoblasts, playing a crucial role in regulating phosphate metabolism. Mutations in the PHEX gene, which is highly expressed in osteocytes and osteoblasts, lead to elevated FGF23 levels. This occurs because abnormal cleavage of FGF23 results in hypophosphatemia due to impaired phosphate reabsorption in the renal proximal tubules (causing reduced NPT2a and 2c transporter activity) and decreased phosphate absorption in the intestines (due to decreased activity of 1α-hydroxylase, which reduces the renal synthesis of 1,25(OH)2D3).

·       A humanized monoclonal antibody for FGF23, known as burosumab, has received approval for treating XLH in pediatric patients aged one year and older. Crysvita® (burosumab) was approved by the FDA and became available in the USA in March 2018. Additionally, it has gained approval from the EMA for use in 28 countries.

 

Thelansis’s “X-Linked Hypophosphatemia (XLH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential X-Linked Hypophosphatemia (XLH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of X-Linked Hypophosphatemia (XLH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

X-Linked Hypophosphatemia (XLH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: X-Linked Hypophosphatemia (XLH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: X-Linked Hypophosphatemia (XLH), X-Linked Hypophosphatemia (XLH) market outlook, X-Linked Hypophosphatemia (XLH) competitive landscape, X-Linked Hypophosphatemia (XLH) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)